COMMUNIQUÉS West-GlobeNewswire

-
PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9
02/05/2024 -
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
02/05/2024 -
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
02/05/2024 -
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
02/05/2024 -
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
02/05/2024 -
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
02/05/2024 -
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
02/05/2024 -
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
02/05/2024 -
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
02/05/2024 -
Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary
02/05/2024 -
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
02/05/2024 -
BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting
02/05/2024 -
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
02/05/2024 -
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
02/05/2024 -
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
02/05/2024 -
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
02/05/2024 -
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
02/05/2024 -
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO
02/05/2024 -
Biogen Reports Progress on Corporate Responsibility Priorities
02/05/2024
Pages